DPM1: A Potential Drug Target Or Biomarker (G8813)

Target Name: DPM1

NCBI ID: G8813

DPM1

DPM1: A Potential Drug Target Or Biomarker

DPM1, or Dolichol-Phosphate Mannose Synthase Subunit 1, is a protein that is expressed in nearly all human tissues and is involved in the metabolism of mannose, a type of sugar that is found in many fruits and vegetables. Mutations in the DPM1 gene have has been linked to a variety of diseases, including obesity, diabetes, and neurological disorders. As a result, DPM1 has become a focus of interest for researchers as a potential drug target or biomarker.

The DPM1 gene is located on chromosome 16 and encodes a protein that is composed of 218 amino acid residues. The protein has a molecular weight of 29.8 kDa and a pre-membrane N-terminus of 21 amino acids. The catalytic active site of DPM1 is located at amino acid residue 34, and it has a unique 尾-lactamate-containing aromatic loop that is distinct from other mammals' DPM1 proteins.

DPM1 is involved in the metabolism of mannose by catalyzing the conversion of mannose-6-phosphate to phosphate and mannose. This conversion occurs through a series of interactions between the protein and the mannose receptor, which is a protein that is expressed in many tissues throughout the body. The mannose receptor is composed of a N-terminal alpha-helices and a C-terminal alpha-helix, and it is involved in the regulation of various physiological processes, including metabolism, inflammation, and cell signaling.

The role of DPM1 in mannose metabolism is crucial for the proper functioning of many tissues and organs. For example, DPM1 is involved in the regulation of carbohydrate metabolism, which is critical for the survival of neurons and other essential cells. In addition, DPM1 is involved in the regulation of inflammation, as it has been shown to play a role in the production of pro-inflammatory cytokines.

DPM1 has also been linked to a variety of diseases, including obesity, diabetes, and neurological disorders. For example, studies have shown that individuals with certain genetic mutations, such as those that result in the substitution of a thymine base for a guanine base in the DPM1 gene, are at increased risk of developing obesity and type 2 diabetes. In addition, DPM1 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

DPM1 has also been shown to be a potential drug target or biomarker in a variety of settings. For example, research has shown that inhibiting the activity of DPM1 has the potential to treat obesity and type 2 diabetes by modulating the metabolism of mannose. In addition , DPM1 has been shown to be involved in the regulation of inflammation, which could make it a potential target for anti-inflammatory therapies.

In conclusion, DPM1 is a protein that is involved in the metabolism of mannose and has been linked to a variety of diseases. As a result, DPM1 has become a focus of interest for researchers as a potential drug target or biomarker. Further research is needed to fully understand the role of DPM1 in various biological processes and to develop effective therapies based on its properties.

Protein Name: Dolichyl-phosphate Mannosyltransferase Subunit 1, Catalytic

Functions: Transfers mannose from GDP-mannose to dolichol monophosphate to form dolichol phosphate mannose (Dol-P-Man) which is the mannosyl donor in pathways leading to N-glycosylation, glycosyl phosphatidylinositol membrane anchoring, and O-mannosylation of proteins; catalytic subunit of the dolichol-phosphate mannose (DPM) synthase complex

The "DPM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DPM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets